Use of an anti-CD151 antibody in the treatment of cancer
US8178096B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Oct 15, 2007 |
| Grant date | May 15, 2012 |
| Priority date | — |
| Expiry date | Oct 15, 2027 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/34
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to the use of at least one antibody, or a functional fragment thereof, which is capable of binding to the CD151 protein and thereby inhibiting tumor growth, in the preparation of a medicament intended for the treatment of cancer.The invention is also directed to a composition for the treatment of cancer, comprising, as active ingredient, at least one anti-CD151 antibody, or a functional fragment thereof, which is capable of binding to the CD151 protein and/or of inhibiting the development of primary tumors and/or of inhibiting its metastasis-promoting activity, which antibodies may consist of the antibodies TS151 and/or TS151r.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.